Ash Stevens Approved as the API Manufacturer for Ixazomib Citrate

Monday, November 23, 2015

Ash Stevens a provider of global contract pharmaceutical chemical development and API (Active Pharmaceutical Ingredient) manufacturing services, has announced that the U.S Food and Drug Administration (FDA) has approved ASI's facility in Riverview, Michigan for the manufacture of the API ixazomib, an oral proteasome inhibitor indicated in combination with leanlidomide and dexamethasone for the treatment of patients multiple myeloma who have received at least one prior therapy.

"Ixazomib is a novel, orally active drug, giving hope to certain patients suffering from multiple myeloma," said Dr. Stephen Munk, CEO and President of Ash Stevens.  "The rapid approval by FDA to manufacture this important drug validates our mission to use chemistry to improve the quality of life for people suffering from a variety of conditions.  We are extremely proud to be manufacturing a second, novel API for Takeda."
  • <<
  • >>

Join the Discussion